HC Wainwright Forecasts Reduced Earnings for Bausch + Lomb

Bausch + Lomb Co. (NYSE:BLCO) – Equities researchers at HC Wainwright dropped their Q1 2025 earnings per share (EPS) estimates for shares of Bausch + Lomb in a report released on Tuesday, February 18th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of $0.20 for the quarter, down from their prior forecast of $0.21. HC Wainwright has a “Buy” rating and a $23.00 price target on the stock. The consensus estimate for Bausch + Lomb’s current full-year earnings is $0.60 per share. HC Wainwright also issued estimates for Bausch + Lomb’s Q2 2025 earnings at $0.23 EPS, Q3 2025 earnings at $0.21 EPS, Q4 2025 earnings at $0.27 EPS and FY2025 earnings at $0.91 EPS.

BLCO has been the subject of a number of other reports. Royal Bank of Canada decreased their target price on shares of Bausch + Lomb from $23.00 to $22.00 and set an “outperform” rating for the company in a research report on Wednesday, January 29th. Bank of America reissued an “underperform” rating and issued a $18.00 price objective on shares of Bausch + Lomb in a report on Thursday, December 12th. Wells Fargo & Company dropped their target price on Bausch + Lomb from $26.00 to $24.00 and set an “overweight” rating on the stock in a report on Thursday, January 16th. Stifel Nicolaus reduced their price target on Bausch + Lomb from $19.00 to $18.00 and set a “hold” rating for the company in a research report on Wednesday, January 29th. Finally, Citigroup lowered Bausch + Lomb from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $24.00 to $22.00 in a research report on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $20.25.

Bausch + Lomb Stock Performance

Shares of NYSE BLCO opened at $16.29 on Wednesday. The company has a 50 day simple moving average of $17.47 and a two-hundred day simple moving average of $18.15. The stock has a market cap of $5.74 billion, a price-to-earnings ratio of -15.51, a PEG ratio of 2.17 and a beta of 0.46. The company has a current ratio of 1.57, a quick ratio of 0.95 and a debt-to-equity ratio of 0.69. Bausch + Lomb has a 12 month low of $13.16 and a 12 month high of $21.69.

Bausch + Lomb (NYSE:BLCO) last released its earnings results on Wednesday, February 19th. The company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.02. Bausch + Lomb had a positive return on equity of 3.17% and a negative net margin of 7.86%. The firm had revenue of $1.28 billion during the quarter, compared to the consensus estimate of $1.26 billion. During the same quarter in the previous year, the company posted $0.24 earnings per share. The company’s revenue was up 9.1% compared to the same quarter last year.

Institutional Trading of Bausch + Lomb

Institutional investors and hedge funds have recently modified their holdings of the stock. Blue Trust Inc. boosted its holdings in Bausch + Lomb by 68.3% in the 4th quarter. Blue Trust Inc. now owns 2,474 shares of the company’s stock worth $48,000 after buying an additional 1,004 shares during the last quarter. State Street Corp lifted its position in shares of Bausch + Lomb by 5.6% in the third quarter. State Street Corp now owns 28,450 shares of the company’s stock valued at $549,000 after acquiring an additional 1,510 shares in the last quarter. HighTower Advisors LLC boosted its stake in shares of Bausch + Lomb by 14.7% in the third quarter. HighTower Advisors LLC now owns 24,661 shares of the company’s stock worth $476,000 after acquiring an additional 3,164 shares during the last quarter. FNY Investment Advisers LLC purchased a new stake in shares of Bausch + Lomb during the fourth quarter worth approximately $72,000. Finally, XTX Topco Ltd raised its stake in Bausch + Lomb by 25.4% in the 4th quarter. XTX Topco Ltd now owns 20,077 shares of the company’s stock valued at $363,000 after purchasing an additional 4,065 shares during the last quarter. Hedge funds and other institutional investors own 11.07% of the company’s stock.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.